Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Intel Corp (INTC) Price & Performance

Abeona Therapeutics IncTrade
Intel CorpTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Intel Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Intel Corp trades at $98.71 (market cap $491.89B). The key difference: Intel Corp is far larger — about 1159.2× Abeona Therapeutics Inc's market cap, and Intel Corp pays a 2.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOINTC
Market Cap
$424.33M$491.89B
Sector
HealthTechnology
52-Week High
$7.45$140.94
52-Week Low
$4.17$21.81
Enterprise Value
$279.23M$512.70B
Volume
43,552,012
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Intel Corp

Intel (INTC) trades at $101.65, up 1.84% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $267 million in 2025 despite revenue of $52.85 billion, though it beat EPS estimates in recent quarters. Recent news highlights a $20 billion stock offering to fund AI expansion, causing short-term volatility but viewed as strategic for long-term growth.

Outlook is mixed: analyst consensus price target of $116.67 suggests upside, supported by AI investments, but high P/E of 904.17 and negative profit margins pose valuation risks. Key risks include intense competition, execution challenges in foundry growth, and reliance on capital raises amid cash burn in strategic segments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

Read more on INTC